

AI ANALYSIS SHOWS ENHANCED CCNG1 EXPRESSION IN SARCOMA: A NOVEL BIOMARKER FOR DELTAREX-G CCNG1 INHIBITOR THERAPY

PRESENTED BY DR. SANT P. CHAWLA AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY

LOS ANGELES, CALIFORNIA, UNITED STATES OF AMERICA, October 24, 2023 /EINPresswire.com/ -- The Aveni Foundation and the <u>Sarcoma</u> Oncology Research Center, Santa Monica CA, are proud to announce the results of a research collaboration with BostonGene Corp., Waltham MA, wherein AI analysis showed enhanced

A Retroviral vector B Tumor targeting C Genetic payloads

S/G-targeting peptide

Tumor microenvironment

S/G proteins

ginature proteins

C Genetic payloads

"Dominant negative" construct

"Dominant negative" construct

Cytocidal dnG1:

Endoced dnG1 expression belief typic enhackpoint functions of Cyclin G1

Tumor blood supply

Artist's Illustration of DeltaRex-G that hunts down tumors and nowhere else and kills cancer cells, cancer stem cells and their blood supply.

CCNG1 oncogene expression in all tumors of patients with osteosarcoma, chondrosarcoma, leiomyosarcoma and other soft tissue sarcomas tested so far (ANN ONCOL VOLUME 34, SUPPLEMENT 2, S1056-S1057, OCTOBER 2023.



Since DeltaRex-G reduces stroma production as well as kills cancer cells, DeltaRex-G enhances immune cell trafficking in the tumor microenvironment, therefore serving as an immune modulator."

Sant P. Chawla, MD

DOI: https://doi.org/10.1016/j.annonc.2023.09.1209).

Currently, a number of patients whose tumors show high, medium high and medium low CCNG1 expression are currently receiving <u>DeltaRex-G</u> as platform therapy upon which other FDA approved cancer drugs/immunotherapies have been added. This regulatory authorization by the United States Food and Drug Administration/Center for Biologics Evaluation Research is based on CCNG1 enhanced expression in all tumors tested and on Phase 1/2 studies demonstrating safety and efficacy of DeltaRex-G for advanced pancreatic cancer, sarcoma, and breast cancer, and long term (>10-year) survival data with DeltaRex-G gene therapy. Prospective Phase 2 studies are

planned to evaluate the safety and efficacy of DeltaRex-G combination regimens, and to

correlate tumor response with CCNG1 expression level in sarcoma tumors (Chawla et al., presented at the European Society of Medical Oncology Annual Meetings, October 20-24,2023).

DeltaRex-G is a targeted gene therapy vector that seeks out the biochemical signatures (SIG) of all invading cancers. Taken off the shelf and injected intravenously, DeltaRex-G effectively tracks down and binds to SIG proteins in the tumor microenvironment and kills rapidly dividing cancer cells, tumor associated fibroblasts and tumor associated microvasculature, without causing the side effects of chemotherapy and ungoverned immunotherapy agents. And since DeltaRex-G reduces stroma production as well as kills cancer cells, DeltaRex-G enhances immune cell trafficking in the tumor microenvironment, therefore serving as an immune modulator, according to Dr. Chawla.

For further information, please go to the following websites:

www.avenifoundation.org,


www.sarcomaoncology.com or contact

Dr. Gordon at

egordon@avenifoundation.org or egordon@sarcomaoncology.com. To

make a donation, please visit our website at www.avenifoundation.org and click on the "donate" button for credit card donations.

Erlinda Maria Gordon Aveni Foundation +1 310-552-9999 email us here



Enhanced Enhanced CCNG1 expression in tumors of patients with osteosarcoma and soft tissue sarcomas: A novel biomarker for DeltaRex-G CCNG1 inhibitor therapy



Our mission is to expedite the development of gene targeted technologies for cancer and Parkinson's

disease.

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.